Home/Specialties/Oncology & Robotic Surgery

Practice · Oncology & Robotic Surgery

A referral engine your tumor board can trust.

We build second-opinion pipelines, robotic surgery demand and radiation-oncology intake — routed through medical triage, not sales dialers.

For Chiefs of Oncology, Surgical Oncology Program Directors and MDs of cancer super-specialty and comprehensive cancer centres.

Request a Oncology Pipeline Blueprint →Review case evidence

Second-Opinion Enquiries

+142%

6-month cohort

Tumor-board Qualified Rate

42%

Uplift vs. baseline

Robotic Case Volume

2.8×

Prostatectomy, 9-mo

International Patient Mix

18%

Of oncology revenue

Procedure-level demand engineering

We target the procedures that move your P&L, not the ones that fill the OPD queue.

CATCHMENT TIER · PRICE RESTATEMENT

ARPU differs materially between Metro, Tier-2 and Tier-3 catchments. Switch tier to restate every procedure band against the payer mix and package ceilings we observe in that market — not a single all-India number.

Viewing Metro / Tier-1 · Representative catchments: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Pune.

Robotic Prostatectomy

₹4.8 L–7.2 L

PSA-triggered second opinion funnel

Head & Neck Onco-Surgery

₹3.2 L–8.0 L

Biopsy-report review pathway

Breast Conservation & Onco-plasty

₹2.8 L–6.5 L

Screening-to-surgery pathway

GI & HPB Oncology

₹4.5 L–14 L

Multi-modal tumor-board funnel

Radiation Oncology (IMRT/SBRT)

₹2.2 L–5.8 L

Post-surgical & primary intake

Medical Oncology (Chemo cycles)

₹1.4 L–3.2 L / cycle

Cycle-adherence & continuity funnel

Methodology. Base bands reflect RDV's engagement dataset across 47 super-specialty hospitals, reconciled against CGHS/ECHS package rates, state-scheme ceilings (Ayushman Bharat PM-JAY, CMCHIS, YSR Aarogyasri) and empanelled TPA grids. Tier multipliers applied: Metro 1.00× · Tier-2 0.72× · Tier-3 0.55×. Actuals swing with payer mix, consultant-fee split and implant/consumable choice — the written Blueprint restates every band against your own HIS billing history before any spend is committed.

Clinical referral pathway

Intent → triage → consult → admission. Instrumented at every gate.

01 · Intent capture
Diagnosis-specific search, patient-support communities, referring physician network.
02 · Medical triage
Report-upload gated intake; oncology nurse navigator qualification.
03 · Tumor-board slotting
Case presented at MDT; treatment plan drafted before first visit.
04 · Multi-modal admission
Surgery + radiation + chemo cycles tracked as a single episode of care.

Case snapshot

42% MDT-qualified rate, 2.8× robotic case volume.

A representative RDV engagement in the Oncology & Robotic Surgery practice line. Individual results vary by catchment, clinical capacity and payer mix.

Setting: Comprehensive cancer centre, 220 beds, Tier-1 metro
Duration: 12 months
Cohort: n = 1,860 diagnosis-uploaded enquiries
Outcome: 42% MDT-qualified rate, 2.8× robotic case volume

Figures engagement-verified against hospital HIS. No outcome guarantees implied; per NMC advertising guidelines.

Why Chiefs of Oncology choose RDV

Trust is earned in the operating logic, not the pitch deck.

Tumor-board-gated intake

Enquiries reach your surgical oncologist as staged cases with imaging and biopsy — not raw phone leads.

Consent-first survivor storytelling

Every patient story cleared under a documented informed-consent workflow. Nothing goes live without signed release.

Cure-claim firewall

No survival percentages, no comparative outcomes, no 'best in India' — NMC-safe language reviewed per asset.

Nurse-navigator triage

Oncology-trained navigators, not sales dialers, run the first patient conversation. Higher trust, higher MDT-qualified rate.

From an engagement

"The tumor-board slotting protocol changed the conversation. Patients arrived with a plan, not a question — our MDT time compressed and conversion tripled."

— Director, Surgical Oncology · 220-bed comprehensive cancer centre

Attribution anonymised per client confidentiality; engagement code verifiable in the founder-led review.

Talk directly to the founding partner who ran this engagement.

Request a Oncology Blueprint →

48-hour founder-led review. Fixed-scope. No lock-in.

Clinical authority

Content your clinicians will co-sign.

Surgical oncologist case-note library (staging + technique)
Tumor-board transparency page (case volume, MDT composition)
Survivor narrative library with informed-consent framework

Compliance posture

Every asset, every claim, medically reviewed.

NMC advertising norms — no cure claims, no comparative survival data
Consent-first survivor storytelling protocol
DPDP-grade handling of diagnostic report uploads

Catchment note: Catchment work across Tier-2 India source cities and international corridors (East Africa, GCC, SAARC).

The 21-day diagnostic

What the fixed-scope engagement actually contains — for Oncology.

No mystery, no scope creep. Each week is instrumented and delivered against a checklist your MD and Chief signs.

Week 1
OPD-to-MDT leakage audit; historical second-opinion funnel teardown.
Week 2
Referring-physician & patient-support-community mapping.
Week 3
Modality mix analysis (surgery / radiation / medical onco) and unit economics.
Week 4
Founder-led review with Chief of Oncology and MDT lead.

Where we compound

The unfair edge — for Oncology specifically.

MDT case-presentation happens before the first physical visit — unique in the category
Corridor-specific international patient programmes (GCC, East Africa, SAARC)
Robotic-surgery demand built around clinical benefit, never device brand

Practice guarantees

What we commit to in writing.

Fixed-scope diagnostic — no retainer, no annual lock-in
HIS-verified attribution — every claimed admission traceable to source
No media markup — you see raw platform invoices at cost
Founder-led — the partner who scopes the engagement does the work

Objections we hear

The three questions MDs ask before signing.

We keep our answers on the record. If yours isn't here, ask it in the qualification form — the founding partner replies personally within 48 hours.

Oncology cannot be marketed ethically.

Direct oncology marketing cannot. Educational second-opinion pathways, tumor-board transparency and consent-based survivor content can — and are the only assets we build. Every claim is NMC-reviewed.

We already have a strong medical-tourism desk.

Then you have a distribution layer. What we add is corridor-specific demand generation feeding that desk with pre-qualified, financially pre-authorised enquiries — measured against confirmed international admissions.

Our tumor board is at capacity.

Good — we don't add volume without adding qualified volume. In practice, better-triaged cases shorten MDT time per patient and free capacity. If not, we throttle intake. Volume without governance is a risk we won't take.

FAQ

The questions Chiefs of Oncology ask us first.

If yours isn't here, put it in the qualification form — our founding partner will answer it in the 48-hour review.

Can oncology be marketed ethically at all?+

Yes — through education, second-opinion pathways and KOL-led content. Every asset is reviewed against NMC norms; we never publish cure rates, survival curves or comparative outcome claims. What we do publish is process, volume and multi-disciplinary rigor.

How does the tumor-board funnel work?+

Enquiries are gated on diagnostic report upload. Oncology nurse navigators structure the case; it is presented at your MDT before the patient's first physical visit. This shifts you from being a treatment option to being the treatment plan.

Do you drive robotic surgery demand without DCGI issues?+

We build demand for the clinical benefit (nerve-sparing, faster recovery, precision margin), not the branded device. Content is co-authored with the operating surgeon and reviewed for DCGI compliance.

What about international patients?+

We build country-specific corridors with visa-facilitation partners, pre-departure MDT calls and financial pre-authorization — turning international intent into confirmed admissions.

Next step